Effects of Sacubitril/Valsartan combined with lyophilized recombinant human brain natriuretic peptide in treatment of patients with chronic heart failure
Objective:To observe effects of Sacubitril/Valsartan combined with lyophilized recombinant human brain natriuretic peptide(rhBNP)in treatment of patients with chronic heart failure(CHF).Methods:A prospective study was conducted on 98 patients with CHF admitted to this hospital from June 2021 to June 2023.According to the random number table method,they were divided into observation group and control group,49 cases in each group.The control group was treated with rhBNP for injection,while the observation group was treated with Sacubitril/Valsartan sodium tablets on the basis of that of the control group.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],the hemorheology index levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.92%(47/49),which was higher than 83.67%(41/49)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the observation was higher than that in the control group;the levels of LVEDD and LVESD in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of whole blood high shear viscosity,whole blood low shear viscosity and plasma viscosity in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sacubitril/Valsartan combined with rhBNP in the treatment of the CHF patients can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of hemorheology indexes.Moreover,it is superior to single rhBNP treatment.
Chronic heart failureLyophilized recombinant human brain natriuretic peptideSacubitril/ValsartanCardiac functionHemorheologyAdverse reaction
NETL
NSTL
万方数据
维普
